Dr. Federico V. Pallardó Calatayud

Principal Investigator
Research Group on Cellular and Organic Physiopathology of Oxidative Stress


Dr. Pallardó studied Medicine at the Faculty of Medicine of the University of Valencia where he graduated in 1985 with the qualification of outstanding where he also obtained his doctorate “cum laude”.
After passing through the universities of Oxford in the United Kingdom and Harvard Medical School in the United States, where he obtained the prestigious NATO fellowship, he returned to Spain in 1992. He is currently a University Professor, being Dean of the Faculty of Medicine and Dentistry from the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School.
He has been director of the Central Research Unit, coordinating the INCLIVA basic research laboratories for more than ten years. He has been the head of the CIBER group in its rare diseases division since 2007.
His research focuses on the role of oxidative stress in the pathophysiology of rare diseases and epigenetic regulation. He has more than 230 scientific publications, is a regular contributor to prestigious international journals and has directed 23 doctoral theses. Its h-index is currently 57 with more than 11,000 accumulated citations. He is a founding partner of the biotechnological company EPIDISEASE S.L. spin-off of the University of Valencia, CIBERER and INCLIVA. It holds four international patents. He directs the CIBERER-Biobank of the ISCIII.

He has been secretary of the SFRR (Europe) and has received various national and international awards such as the Fundación Salud 2000 Award for his research into rare diseases or the international project Saving lives at Birth from the Bill and Melinda Gates Foundation. He has been awarded the “SFRR-Europe Annual Award Lecture” by the Society for Free Radical Research in its 2020 edition.
He has been an advisory member of the Valencian Foundation for Advanced Studies and Jury of the Jaime I research awards on several occasions. He is an evaluator of research projects for national organizations from different countries in Europe and Latin America. He belongs to the editorial committee of several journals and is editor of “Redox Biology”

Dr. Federico V. Pallardó Calatayud
Dr. Federico V. Pallardó Calatayud


Age-Related microRNA overexpression in Lafora disease male mice provides links between neuroinflammation and oxidative stress. Roma-Mateo C, Lorente-Pozo S, Marquez-Thibaut L, Moreno-Estelles M, Garces C, Gonzalez D, Lahuerta M, Aguado C, Garcia-Gimenez JL, Sanz P, Pallardo FV. International Journal of Molecular Sciences. 2023 Jan 6;24(2):1089. doi: 10.3390/ijms24021089. PMID: 36674605

Characterization of Early Peripheral Immune Responses in Patients with Sepsis and Septic Shock. Beltran-Garcia J, Osca-Verdegal R, Javega B, Herrera G, O’Connor J, Garcia-Lopez E, Casabo-Valles G, Rodriguez-Gimillo M, Ferreres J, Carbonell N, Pallardo F, Garcia-Gimenez J. Biomedicines. 2022 Feb 23;10(3):525. doi: 10.3390/biomedicines10030525. PMID: 35327327

CIBERER: Spanish national network for research on rare diseases: a highly productive collaborative initiative. Luque J, Mendes I, Gomez B, Morte B, de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Perez-Jurado L, Montoliu L, Carracedo A, Millan J, Webb S, Palau F, Lapunzina P, Pallardo Calatayud F, CIBERER Network. Clinical Genetics. 2022 May;101(5-6):481-493. doi: 10.1111/cge.14113. PMID: 35060122

Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Journal of Inflammation Research. 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852

Extracellular histones trigger oxidative stress-dependent induction of the NF-kB/CAM pathway via TLR4 in endothelial cells. Perez-Cremades D, Bueno-Beti C, Garcia-Gimenez J, Ibanez-Cabellos J, Pallardo F, Hermenegildo C, Novella S. Journal of Physiology and Biochemistry. 2022 Dec 5. doi: 10.1007/s13105-022-00935-z. PMID: 36464762

Histone citrullination mediates a protective role in endothelium and modulates inflammation. Osca-Verdegal R, Beltran-Garcia J, Paes A, Nacher-Sendra E, Novella S, Hermenegildo C, Carbonell N, Garcia-Gimenez J, Pallardo F. Cells. 2022 Dec 15;11(24):4070. doi: 10.3390/cells11244070. PMID: 36552833

Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies. Garcia-Gimenez JL, Garcia-Trevijano ER, Aviles-Alia AI, Ibanez-Cabellos JS, Bovea-Marco M, Bas T, Pallardo FV, Vina JR, Zaragoza R. Orphanet Journal of Rare Diseases. 2022 Dec 27;17(1):450. doi: 10.1186/s13023-022-02603-3. PMID: 36575500

Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity. Saadi W, Fatmi A, Pallardo FV, Garcia-Gimenez JL, Mena-Molla S. Cancers. 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184. PMID: 36612180

Neurodevelopmental outcome and epigenetic changes at 2 years associated with the oxygen load received upon postnatal stabilization: a pilot study. Lorente-Pozo S, Boronat N, Parra-Llorca A, Lara-Canton I, Solaz-Garcia A, Soler J, Buso E, Casabo-Valles G, Garcia-Gimenez J, Pallardo F, Vento M. Neonatology. 2022;119(5):575-584. doi: 10.1159/000525305. PMID: 35760056

The endothelial glycocalyx and neonatal sepsis. Fatmi A, Saadi W, Beltran-Garcia J, Garcia-Gimenez JL, Pallardo FV. International Journal of Molecular Sciences. 2022 Dec 26;24(1):364. doi: 10.3390/ijms24010364. PMID: 36613805

The genetic diversity and dysfunctionality of catalase associated with a worse outcome in Crohn’s Disease. Iborra M, Moret I, Buso E, Garcia-Gimenez J, Ricart E, Gisbert J, Cabre E, Esteve M, Marquez-Mosquera L, Garcia-Planella E, Guardiola J, Pallardo F, Serena C, Algaba-Chueca F, Domenech E, Nos P, Beltran B. International Journal of Molecular Sciences. 2022 Dec 14;23(24):15881. doi: 10.3390/ijms232415881. PMID: 36555526

Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Antioxidants. 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668

Clinical and immunological aspects of microRNAs in neonatal sepsis. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-Lopez M, Aribi M, Pallardo FV, Garcia-Gimenez JL. Biomedicine & Pharmacotherapy. 2021 Nov 19;145:112444. doi: 10.1016/j.biopha.2021.112444. PMID: 34808550

Cofilin and neurodegeneration: new functions for an old but gold protein. Lapena-Luzon T, Rodriguez L, Beltran-Beltran V, Beneto N, Pallardo F, Gonzalez-Cabo P. Brain Sciences. 2021 Jul 20;11(7):954. doi: 10.3390/brainsci11070954. PMID: 34356188

Comparative analysis of chromatin-delivered biomarkers in the monitoring of sepsis and septic shock: a pilot study. Beltran-Garcia J, Manclus J, Garcia-Lopez E, Carbonell N, Ferreres J, Rodriguez-Gimillo M, Garces C, Pallardo F, Garcia-Gimenez J, Montoya A, Roma-Mateo C. International Journal of Molecular Sciences. 2021 Sep 14;22(18):9935. doi: 10.3390/ijms22189935. PMID: 34576097

DNA Methylation Analysis to Unravel Altered Genetic Pathways Underlying Early Onset and Late Onset Neonatal Sepsis. A Pilot Study. Lorente-Pozo S, Navarrete P, Garzón MJ, Lara-Cantón I, Beltrán-García J, Osca-Verdegal R, Mena-Mollá S, García-López E, Vento M, Pallardó FV, García-Giménez JL. Frontiers in Immunology. 2021 Feb 15;12:622599. doi: 10.3389/fimmu.2021.622599. PMID: 33659006

Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Pallardo Calatayud F, Pagano G, Rodriguez Melguizo L, González Cabo P, Lyakhovich A, Trifuoggi M. Translational Research. 2021 Mar;229:135-141. doi: 10.1016/j.trsl.2020.08.009. PMID: 32841735

IGF-1 haploinsufficiency causes age-related chronic cochlear inflammation and increases noise-induced hearing loss. Celaya A, Rodriguez-De la Rosa L, Bermudez-Munoz J, Zubeldia J, Roma-Mateo C, Avendano C, Pallardo F, Varela-Nieto I. Cells. 2021 Jul 3;10(7):1686. doi: 10.3390/cells10071686. PMID: 34359856

Implementing Precision Medicine in Human Frailty through Epigenetic Biomarkers. Garcia-Gimenez J, Mena-Molla S, Tarazona-Santabalbina F, Vina J, Gomez-Cabrera M, Pallardo F. International Journal of Environmental Research and Public Health. 2021 Feb 15;18(4):1883. doi: 10.3390/ijerph18041883. PMID: 33672064

Mitigating the pro-oxidant state and melanogenesis of Retinitis pigmentosa: by counteracting mitochondrial dysfunction. Pagano G, Pallardo F, Lyakhovich A, Tiano L, Trifuoggi M. Cellular and Molecular Life Sciences. 2021 Dec;78(23):7491-7503. doi: 10.1007/s00018-021-04007-1. PMID: 34718826

Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. Pagano G, Manfredi C, Pallardo Calatayud F, Lyakhovich A, Tiano L, Trifuoggi M. Inflammation Research. 2021 Feb;70(2):159-170. doi: 10.1007/s00011-020-01423-0. PMID: 33346851

Role of adenosine receptors in rare neurodegenerative diseases with motor symptoms. Beltran-Beltran V, Beneto N, Lapena-Luzon T, Rodriguez LR, Pallardo FV, Gonzalez-Cabo P. Current Protein & Peptide Science. 2021 Dec 27;22(9):675-694. doi: 10.2174/1389203722666210910110126. PMID: 34514988

Role of microRNAs as biomarkers in sepsis-associated encephalopathy. Osca-Verdegal R, Beltran-Garcia J, Pallardo FV, Garcia-Gimenez JL. Molecular Neurobiology. 2021 Sep;58(9):4682-4693. doi: 10.1007/s12035-021-02445-3. PMID: 34160774

Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis. Beltran Garcia J, Osca Verdegal R, Nacher Sendra E, Cardona Monzonis A, Sanchis Gomar F, Carbonell N, Pallardo FV, Lavie CJ, Garcia Gimenez JL. Progress in Cardiovascular Diseases. 2021;68:70-77. doi: 10.1016/j.pcad.2021.07.005. PMID: 34265333

Acute depletion of telomerase components DKC1 and NOP10 induces oxidative stress and disrupts ribosomal biogenesis via NPM1 and activation of the P53 pathway. Ibañez Cabellos S, Seco Cervera M, Picher Latorre C, Pérez Machado G, Garcia Gimenez J, Pallardo Calatayud F. Biochimica Et Biophysica Acta-Molecular. Cell Research. 2020 Dec;1867(12):118845. doi: 10.1016/j.bbamcr.2020.118845. PMID: 32910990

Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures. Pagano G, Pallardo Calatayud F, Lyakhovich A, Tiano L, Fittipaldi M, Toscanesi M, Trifuoggi M. International Journal of Molecular Sciences. 2020 Sep 25;21(19):7060. doi: 10.3390/ijms21197060. PMID: 32992778

Circular RNAs in Sepsis: Biogenesis, Function, and Clinical Significance. Beltrán García J, Osca Verdegal R, Nacher-Sendra E, Pallardo Calatayud F, Garcia Gimenez J. Cells. 2020 Jun 25;9(6):1544. doi: 10.3390/cells9061544. PMID: 32630422

Cofilin dysregulation alters actin turnover in frataxin-deficient neurons. Muñoz Lasso D, Molla B, Calap Quintana P, Garcia Gimenez J, Pallardo Calatayud F, Palau F, González Cabo P. Scientific Reports. 2020 Mar 23;10(1):5207. doi: 10.1038/s41598-020-62050-7. PMID: 32251310

Correction to: miRNA-23b as a biomarker of culture-positive neonatal sepsis. Fatmi A, Rebiahi S, Chabni N, Zerrouki H, Azzaoui H, Elhabiri Y, Benmansour S, Ibanez-Cabellos J, Smahi M, Aribi M, Garcia-Gimenez J, Pallardo F. Molecular Medicine. 2020 Dec 14;26(1):129. doi: 10.1186/s10020-020-00257-0. PMID: 33317443

Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression. Beltrán García J, Osca-Verdegal R, Roma Mateo C, Carbonell Monleon N, Ferreres Franco J, Rodriguez M, Mulet Mascarell S, Garcia-Lopez E, Pallardo Calatayud F, Garcia Gimenez J. Epigenomics. 2020 Apr;12(7):617-646. doi: 10.2217/epi-2019-0329. PMID: 32396480

From genetics to epigenetics to unravel the etiology of adolescent idiopathic scoliosis. Perez-Machado G, Berenguer-Pascual E, Bovea-Marco M, Rubio-Belmar P, Garcia-Lopez E, Garzon M, Mena Molla S, Pallardo Calatayud F, Bas T, Viña Ribes J, Garcia Gimenez J. Bone. 2020 Nov;140:115563. doi: 10.1016/j.bone.2020.115563. PMID: 32768685

miRNA-23b as a biomarker of culture-positive neonatal sepsis. Fatmi A, Rebiahi S, Chabni N, Zerrouki H, Azzaoui H, Elhabiri Y, Benmassour S, Ibañez Cabellos S, Smahi M, Aribi M, Garcia Gimenez J, Pallardo Calatayud F. Molecular medicine. 2020 Oct 8;26(1):94. doi: 10.1186/s10020-020-00217-8. PMID: 33032520

Mitoprotective Clinical Strategies in Type 2 Diabetes and Fanconi Anemia Patients: Suggestions for Clinical Management of Mitochondrial Dysfunction. Pagano G, Pallardo Calatayud F, Porto B, Fittipaldi M, Lyakhovich A, Trifuoggi M. Antioxidants. 2020 Jan 18;9(1):82. doi: 10.3390/antiox9010082.PMID: 31963742

Much More Than a Scaffold: Cytoskeletal Proteins in Neurological Disorders. Muñoz Lasso D, Roma Mateo C, Pallardo Calatayud F, González Cabo P. Cells. 2020 Feb 4;9(2):358. doi: 10.3390/cells9020358. PMID: 32033020

Non-coding RNAs and Coronary Artery Disease. Cardona-Monzonis A, Garcia Gimenez J, Mena Molla S, Pareja Galeano H, De La Guia-Galipienso F, Lippi G, Pallardo Calatayud F, Sanchis Gomar F. Advances in Experimental Medicine and Biology. 2020;1229:273-285. doi: 10.1007/978-981-15-1671-9_16. PMID: 32285418

Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. Beltrán García J, Osca Verdegal R, Pallardo Calatayud F, Ferreres Franco J, Rodríguez González M, Mulet Mascarell S, Sanchis Gomar F, Carbonell Monleon N, Garcia Gimenez J. Antioxidants (Basel, Switzerland). 2020 Sep 29;9(10):936. doi: 10.3390/antiox9100936. PMID: 33003552

Oxidative stress modulates rearrangement of endoplasmic reticulum-mitochondria contacts and calcium dysregulation in a Friedreich’s ataxia model. Rodríguez LR, Calap-Quintana P, Lapeña-Luzón T, Pallardó FV, Schneuwly S, Navarro JA, Gonzalez-Cabo P. Redox Biology. 2020 Oct 16;37:101762. doi: 10.1016/j.redox.2020.101762. PMID: 33128998

Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration. Espinos C, Galindo M, Garcia-Gimeno M, Ibañez Cabellos S, Martinez-Rubio D, Millan J, Rodrigo R, Sanz P, Seco Cervera M, Sevilla T, Tapia A, Pallardo Calatayud F. Antioxidants. 2020 Apr 15;9(4):313. doi: 10.3390/antiox9040313. PMID: 32326494

Oxygen in the neonatal period: Oxidative stress, oxygen load and epigenetic changes. Lorente-Pozo S, Parra-Llorca A, Lara-Canton I, Solaz A, Garcia Gimenez J, Pallardo Calatayud F, Vento M. Seminars in Fetal & Neonatal Medicine. 2020 Apr;25(2):101090. doi: 10.1016/j.siny.2020.101090. PMID: 32014366

PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Rodriguez-Pascau L, Britti E, Calap Quintana P, Dong Y, Vergara C, Delaspre F, Medina M, Tamarit J, Pallardo Calatayud F, González Cabo P, Ros J, Lynch D, Martinell M, Pizcueta P. Neurobiology of Disease. 2020 Nov 7;148:105162. doi: 10.1016/j.nbd.2020.105162. PMID: 33171227

Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age. Lahuerta M, Gonzalez D, Aguado C, Fathinajafabadi A, Garcia Gimenez J, Moreno-Estelles M, Roma Mateo C, Knecht E, Pallardo Calatayud F, Sanz P. Molecular Neurobiology. 2020 Mar;57(3):1607-1621. doi: 10.1007/s12035-019-01842-z. PMID: 31808062

Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. Beltrán García J, Osca Verdegal R, Pallardo Calatayud F, Ferreres Franco J, Rodríguez González M, Mulet Mascarell S, Ferrando Sánchez C, Carbonell Monleon N, Garcia Gimenez J. Critical Care Medicine. 2020 Aug 18;10.1097/CCM.0000000000004625. doi: 10.1097/CCM.0000000000004625. PMID: 32826431

Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia. Seco-Cervera M, Gonzalez-Cabo P, Pallardo F, Roma-Mateo C, Garcia-Gimenez J. Antioxidants. 2020 Dec 10;9(12):E1257. doi: 10.3390/antiox9121257. PMID: 33321938

Reference: PI22/00507
Title: Reposicionamiento del Ácido Clavulánico como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos.
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico V. Pallardó Calatayud, Juan Antonio Navarro Langa
Duration: 2023 – 2025
Total budget: 147.620,00 €
Reference: DTS21/00193
Title: Test basados en péptidos spike-in y espectrometría de masas para la cuantificación de histonas circulantes y proteína APC, para el manejo clínico del paciente crítico
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Jose Luis García Giménez
Duration: 2022 – 2023
Total budget: 122.100 €
Reference: IFEQ22/00178
Title: Sistema de espectrometría de masas acoplado a un sistema de cromatografía líquida de alta precisión
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2022 – 2022
Total budget: 300.000 €
Reference: GVA-COVID19/2021/028
Title: Efecto de la infección por COVID-19 sobre la longitud del telómero y parámetros de función mitocondrial y su relación con la evolución a fibrosis pulmonar de tipo idiopático
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 62.280 €
Reference: 90/C/2020
Title: Therapeutical strategies for cystinuria
Funding body: Marató TV3
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2021 – 2023
Total budget: 35.580 €
Reference: AP-2021-009
Title: NATAX: Nanozimas como aproximación terapéutica para el tratamiento del estrés oxidativo en la ataxia de Friedreich
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: José Vicente Ros Lis, Federico V. Pallardó Calatayud
Duration: 2021 – 2022
Total budget: 4.750 €
Reference: PI19/01084
Title: Nuevas terapias en ataxia de Friedreich
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2020 – 2022
Total budget: 93.170 €
Reference: PROMETEO/2018/135
Title: From genes to therapy in neurodegenerative and neuromuscular disorders
Funding body: Conselleria de Educación, Investigación, Cultura y Deporte
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2021
Total budget: 310.506 €
Reference: DTS17/00132
Title: Kit multiplex para la detección simultánea de biomarcadores de diagnóstico y pronóstico de sepsis y shock séptico por espectrometría de masas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2018 – 2020
Total budget: 78.210 €
Reference: PI16/01031
Title: Respuestas epigenéticas a cambios en el entorno redox nuclear. Posibles dianas terapéuticas en enfermedades raras
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2017 – 2019
Total budget: 105.875 €
Reference: CB06/07/0073
Title: CIBER de Enfermedades Raras (CIBERer)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2007 –
Total budget:
+ Info
Title: Uso de las histonas circulantes y sus modificaciones post-traduccionales como biomarcadores en sepsis y shock séptico
Doctoral candidate: Beltrán García, Jesús
Director(s): García Giménez, José Luis; Pallardó Calatayud, Federico
Date of the defense: 20/01/2022
University: Universitat de València

Title: Proteínas nucleares y otros mediadores de inflamación en pacientes en shock séptico sometidos a terapias de remplazo renal
Doctoral candidate: Crespo Gomez, Mónica
Director(s): Cervera Montes, Manuel; Pallardó Calatayud, Federico; Romá Mateo, Carlos
Date of the defense: 25/06/2021
University: Universitat de València